Privacy notice for how Simulations Plus handles personal data in its Learning Management System.
DPA Suppliers and Distributors
Simulations Plus data processing agreement for distributors, resellers, and service providers.
In Vitro Oral Cavity Permeability Assessment to Enable Simulation of Drug Absorption
The oral cavity represents a convenient route of administration for drugs that exhibit significant hepatic first-pass extraction.
Enhancing Solubility in VHL-Based PROTACs: Optimized USP7 Degraders for Improved Developability
Limited aqueous solubility, high total polar surface area (TPSA), and high hydrogen-bond donor (HBD) counts have hampered the clinical development of VHL-based proteolysis-targeting chimeras (PROTACs).
Oral Absorption of Semaglutide: Pharmacokinetic Modeling and Molecular Dynamics Simulations
Semaglutide is a GLP-1 receptor agonist that is formulated for oral administration as Rybelsus®.
Simulations Plus Invests in Clinical Development Technology Company Nurocor
Investment to accelerate innovations in biopharma development through Corporate Development Initiative
Simulations Plus Reports Third Quarter Fiscal 2025 Financial Results
Updated full-year revenue guidance of between $76 to $80 million and adjusted diluted EPS of $0.93 to $1.06
Physiologically Based Pharmacokinetic Modeling and Mechanistic In Vitro-In Vivo Correlation for Long-Acting Injectable Suspension
Long acting injectable (LAI) suspensions demonstrate extended release by forming depots at the injection site (subcutaneous or intramuscular), from which poorly soluble drugs are slowly dissolved and absorbed into the systemic circulation
When Mechanistic IVIVC Falls Short: The Case for IVIVR in Oral Drug Delivery
Traditional IVIVC is robust for ER formulations where dissolution is rate limiting.
Prediction of Monoclonal Antibody Pharmacokinetics in Pediatric Populations Using PBPK Modeling and Simulation
Accurately determining pediatric dosing is essential prior to initiating clinical trials or administering medications in routine clinical settings.
Optimizing Extended-release Formulation of l-tetrahydropalmatine Based on In Vivo Outcomes Using Integrated Modeling Approaches
l-Tetrahydropalmatine (l-THP) is a promising drug candidate for addiction treatment and needs to be delivered in extended-release dosage forms for safety and efficiency.
Structure-Based Screening of Small-Molecule Interleukin-23 Inhibitors Inspired by Monoclonal Antibody Interactions
Interleukin-23 (IL-23) is a key driver of chronic inflammatory diseases, yet current therapies rely on costly monoclonal antibodies.
Thriving in the GenAI Era: A Guide for Scientists
In systems biology, we often speak of emergence—how complex systems yield behaviors not apparent from their individual parts.
Simulations Plus Announces Preliminary Third Quarter Fiscal 2025 Revenue
Updates fiscal 2025 revenue guidance range
Third quarter fiscal 2025 full results to be released on July 2, 2025, with conference call at 5 p.m. ET
Simulations Plus Announces Preliminary Third Quarter Fiscal 2025 Revenue
Updates fiscal 2025 revenue guidance range
Third quarter fiscal 2025 full results to be released on July 2, 2025, with conference call at 5 p.m. ET
Reversal of a Synthetic Opioid Overdose: Insights From a Validated Translational Model
Synthetic opioids are linked to >90 % of opioid overdose deaths in the United States.
Solid-State Evaluation of a Newly Emerged Polymorph for Early-Stage Pharmaceutical Development
This work presents the solid-state evaluation of a new polymorph (Form M) discovered during the early-stage pharmaceutical development of a new chemical entity GDC-6599.
Identification of a Novel Indolizine RORγT Inverse Agonist Using the AI-Driven Drug Design Platform
Automated multiparameter optimization (MPO) at the point of initial drug design is a powerful emerging approach to improve and expedite drug development.
Establishing Virtual Bioequivalence and Bio-related Dissolution Specifications for Naproxen Using Physiologically Based Pharmacokinetic Modeling and in vitro Biorelevant Dissolution Testing
The aim of the present study was to assess the accuracy of the PBPK model in predicting the pharmacokinetic behavior of weakly acidic BCS class II drugs in humans through a multipronged approach of in vitro dissolution, in vivo studies, and in silico simulations.